Recent Updates
Recently added Catalysts
PLRX Positive Sentiment

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pliant Therapeutics has reported strong enrollment in its Phase 1b trial for PLN-101095, indicating positive momentum in its clinical development. Additionally, the company has strengthened its leadership by appointing seasoned oncology experts Flavia Borellini and Robert Iannone to its Board of Directors. These developments reflect Pliant's commitment to advancing its therapeutic pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong enrollment in the Phase 1b trial of PLN-101095.
  • Appointment of experienced leaders to the Board of Directors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
1.5%
average across 6 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
PLN-101095
Phase 1 · Advanced or Metastatic Solid Tumor

Full Press Release Details

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors SOUTH SAN FRANCISCO, Calif., Aug.

Frequently Asked Questions

What is the focus of the PLN-101095 trial?

The PLN-101095 trial is a Phase 1b indication expansion trial.

Who were appointed to the Board of Directors?

Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. were appointed.

Where is Pliant Therapeutics located?

Pliant Therapeutics is based in South San Francisco, California.

What does strong enrollment indicate?

Strong enrollment indicates positive momentum for the trial's progress.

ShareAdd on Google
Tags: PLRX Viatris Investor Conferences Healthcare PLN-101095 Phase 1b Flavia Borellini Robert Iannone
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$158M liquidity · $8M/mo burn
~20 mo
Low dilution risk
Lead asset
PLN-101095Phase 1
Advanced or Metastatic Solid Tumor →

Catalyst track record

+47%
best trade around PLRX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for PLRX.

See every catalyst's timing & PoA →